Answer to Question 1
Correct Answer: 3
Rationale 1: While some states mandate that APRNs can only prescribe under the supervision of a physician, this is not applicable for all states and is not an appropriate statement to include in the lecture.
Rationale 2: APRNs prescribe medication based on state regulations, not federal regulations.
Rationale 3: APRNs prescribe medication based on state regulations. This is an appropriate statement to include in the lecture.
Rationale 4: APRNs prescribe medication based on state regulations, not local regulations.
Global Rationale: APRNs prescribe medication based on state regulations. While some states mandate that APRNs can only prescribe under the supervision of a physician, this is not applicable for all states and is not an appropriate statement to include in the lecture.
Answer to Question 2
Correct Answer: 1,2,3,4
Rationale 1: The primary focus of a clinical trial is to provide information regarding the effectiveness of the research drug. The effectiveness of the research drug will be compared to an inert substance taken by a nontreatment group, called the control group.
Rationale 2: The primary focus of a clinical trial is to provide information regarding the effectiveness of the research drug. The effectiveness of the research drug will be compared to an inert substance taken by a nontreatment group, called the control group.
Rationale 3: Clients may have a perceived or actual improvement in a medical condition if they know they are taking the research drug. Clients may also feel there is no improvement if they know they are taking a drug that has inert properties.
Rationale 4: If the research drug continues to show that it is effective and safe, an NDA will be submitted to the Federal Drug Administration (FDA).
Rationale 5: In some cases, the research drug may be compared to a standard drug used for the same condition, but only during clinical trials. Preclinical research does not include testing on humans.
Global Rationale: The primary focus of a clinical trial is to provide information regarding the effectiveness of the research drug. The effectiveness of the research drug will be compared to an inert substance taken by a nontreatment group, called the control group. If the research drug continues to show that it is effective and safe, an NDA will be submitted to the Federal Drug Administration (FDA). In some cases, the research drug may be compared to a standard drug used for the same condition, but only during clinical trials. Preclinical research does not include testing on humans.